Baseimmune Secures $11.3 Million Series A Investment for Accelerated Development of AI-Designed Cross-Protective Vaccines
Company: Baseimmune
Indication: - African swine fever - Coronavirus - Malaria
Drug: AI-designed cross-protective vaccine candidates
Trial Phase: N/A
NCT ID: N/A
Overview
Baseimmune is a biotechnological firm committed to leading vaccine innovation using a proprietary artificial intelligence algorithm. The company has secured an $11.3 million investment to advance the development of vaccine candidates targeting several diseases.
With the Series A funding led by MSD Global Health Innovation Fund and IQ Capital, Baseimmune plans to expedite the progress of preclinical studies for vaccines against African swine fever, coronavirus, and malaria. The investment also supports the company's growth initiatives, including hiring, adding new programs, and launching more vaccine projects rapidly.
Leveraging their computational platform, Baseimmune aims to reduce vaccine development timelines by utilizing extensive datasets encompassing genomic, immunological, clinical, and evolutionary aspects. The outcome is synthetic antigenic proteins designed to elicit a robust immune defense. Baseimmune's vaccines are compatible with multiple technological platforms, suggesting potential universal vaccines that provide wide-ranging protection, including against novel strains.
The company emerged from the expertise of its founders, Joshua Blight, Ariane Gomes, and Phillip Kemlo, who have a history of pioneering vaccine designs through computational methods at the Jenner Institute, University of Oxford. Their work has led to numerous vaccine candidates entering clinical trials, showcasing Baseimmune's capacity to revolutionize vaccine development and pandemic preparedness.